Press Coverage

AI in Life Sciences Finds an Early Success and Will Continue in 2025

Fran Brown highlights how AI in life sciences drives more precise drug development and reduces…

CertaraDecember 24, 2024

Blog

CMS cell and gene therapy (CGT) access model explained: The most significant drug pricing legislation you’ve never heard of

December 13, 2024 The Centers for Medicare & Medicaid Services (CMS) is piloting a program…

CertaraDecember 13, 2024

Publication

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…

CertaraDecember 9, 2024

Poster

Efficient Phase 1 Selection of CAR-T and Lymphodepletion Regimens Using Augmented Definitive Screening Design

How an augmented definitive screening design identified CAR-T and lymphodepletion regimens with 2.37-fold higher odds…

CertaraNovember 20, 2024

Publication

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

CertaraNovember 7, 2024

Poster

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors

Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult…

CertaraSeptember 16, 2024

Poster

Blinatumomab Trimer Formation

Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…

CertaraSeptember 16, 2024

Blog

4 ways that mechanistic modeling accelerates bispecific (and multispecific) antibody drug development

With nine FDA-approved drugs today, 100+ in clinical development and several hundred in the preclinical…

CertaraSeptember 12, 2024

Poster

Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)

Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…

CertaraSeptember 9, 2024

Poster

Optimizing Avidity of Bispecific Drugs

Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…

CertaraSeptember 9, 2024

Biologics

AI in Life Sciences Finds an Early Success and Will Continue in 2025

CMS cell and gene therapy (CGT) access model explained: The most significant drug pricing legislation you’ve never heard of

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

Efficient Phase 1 Selection of CAR-T and Lymphodepletion Regimens Using Augmented Definitive Screening Design

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors

Blinatumomab Trimer Formation

4 ways that mechanistic modeling accelerates bispecific (and multispecific) antibody drug development

Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)

Optimizing Avidity of Bispecific Drugs

Newsletter sign up

Quick links

Solutions

Contact